Abstract Number: 0573 • ACR Convergence 2021
Biosimilar to Biosimilar Infliximab Switching in Real-world Patients with Inflammatory Arthritis Followed in the Danish DANBIO Registry: Switch from Originator Infliximab to CT-P13 and Then to GP1111
Background/Purpose: In routine care, biosimilar to biosimilar infliximab switching may occur to save costs (=non-medical switching). Previous studies have investigated the efficacy and safety of…Abstract Number: 0604 • ACR Convergence 2021
Disparities in Burden of Disease in Patients with RA Across Racial and Ethnic Groups
Background/Purpose: Prior research has shown that differences exist in disease activity and clinical outcomes for RA across racial and ethnic groups in the US.1 This…Abstract Number: 0757 • ACR Convergence 2021
Different Versions of the Patient Global Question in Rheumatoid Arthritis – Does It Really Matter? – Results of a Multi-center Observational Study
Background/Purpose: The patient global assessment (PGA), typically assessed as 'Considering all of the ways your arthritis has affected you, how do you feel your arthritis…Abstract Number: 0799 • ACR Convergence 2021
Relationships of Rheumatology Care and Patient Experiences to Rheumatoid Arthritis Remission
Background/Purpose: Remission is a well-established optimal outcome in rheumatoid arthritis (RA) treatment, yet a minority of patients reach this goal. There is not one recognized…Abstract Number: 0817 • ACR Convergence 2021
Biosimilar Infliximab Therapy in Rheumatoid Arthritis, Axial Spondyloarthritis and Psoriatic Arthritis: A Long-term Follow-up Study on Infliximab-naive Patients and Switched Patients from the Originator to the Biosimilar CT-P13
Background/Purpose: ReFLECT study has been carried out to investigate real life use of CT-P13, the first monoclonal antibody biosimilar to infliximab (IFX) originator.Methods: ReFLECT is…Abstract Number: 0834 • ACR Convergence 2021
Comparative Effectiveness of TNF Inhibitor vs IL-6 Receptor Inhibitor as Monotherapy or Combination Therapy with Methotrexate in Patients with Rheumatoid Arthritis: Analysis from CorEvitas’ RA Registry
Background/Purpose: RA patients who fail to achieve treatment targets with conventional synthetic DMARDs (csDMARDs) can be treated with biologics. Randomized controlled trials (RCTs) have shown…Abstract Number: 0968 • ACR Convergence 2021
Granzyme K+ CD8 T Cells Form the Core Population of Inflamed Human Tissue-associated CD8 T Cells
Background/Purpose: T cell-derived pro-inflammatory cytokines are a major driver of rheumatoid arthritis (RA) pathogenesis. While CD4 T cells have traditionally been assumed to be the…Abstract Number: 1019 • ACR Convergence 2021
Cigarette Smoking Induces Post-translational Protein Modifications in Both in Vitro and in Vivo Models of Rheumatoid Arthritis-associated Interstitial Lung Disease
Background/Purpose: Cigarette smoking has been epidemiologically linked to the development of ACPA+ rheumatoid arthritis (RA) and, by extension, RA-associated interstitial lung disease (RA-ILD). Providing strong…Abstract Number: 1160 • ACR Convergence 2021
Evaluation of HCQ Side Effects in New and Prevalent Users over a 20 Year Period Using a Large Database
Background/Purpose: Despite being used for more than 70 years as a conventional (cs) DMARD, very little is known about the overall side effect (SE) profile…Abstract Number: 1210 • ACR Convergence 2021
Frequency of Anterior Atlanto-Axial Subluxation in Patients with Rheumatoid Arthritis
Background/Purpose: According to some series, cervical spine is the second most affected region in Rheumatoid arthritis (RA). Cervical involvement was reported in 80% of RA…Abstract Number: 1226 • ACR Convergence 2021
The Neuro-QOL Upper Extremity Function Scale: New Opportunities to More Reliably and Precisely Measure Self-reported Hand Function and Self-care Activities in People with RA
Background/Purpose: RA is an inflammatory disease that results in pain and loss of function, especially in the hands and wrists. Brief self-assessment tools that can…Abstract Number: 1242 • ACR Convergence 2021
Sex Differences in Treatment Response to Three Different Biological Treatments and Corticosteroids in Patients with Early Rheumatoid Arthritis
Background/Purpose: To investigate sex differences in clinical response to three different biological treatments in combination with methotrexate (MTX) versus MTX plus corticosteroids (active conventional treatment;…Abstract Number: 1385 • ACR Convergence 2021
Overall Survival in Patients with Systemic Autoimmune Diseases Following Lung or Heart-Lung Transplantation at a Single High-Volume Academic Transplant Center: A Comparative Cohort Study
Background/Purpose: Lung manifestations of systemic autoimmune diseases are a frequent cause of early death. For many patients, current treatments cannot arrest the inexorable progression to…Abstract Number: 1545 • ACR Convergence 2021
Safety of JAK Inhibitor in Patients with Rheumatoid Arthritis Who Developed Reactivation of Herpes Zoster Virus After Receiving JAK Inhibitor
Background/Purpose: Janus kinase inhibitor (JAKi) increases the risk of the reactivation of herpes zoster (HZ) virus and may thus be temporarily discontinued in cases of…Abstract Number: 1658 • ACR Convergence 2021
Risk of Other Autoimmune Conditions Among Relatives of Patients with Rheumatoid Arthritis
Background/Purpose: Autoimmune conditions appear to cluster in families, as may be expected by shared genetic risk factors in conditions such as rheumatoid arthritis (RA), autoimmune…
- « Previous Page
- 1
- …
- 146
- 147
- 148
- 149
- 150
- …
- 219
- Next Page »
